Epiodyne

📍 San Francisco, United States🗓 Founded 2016👥 3 employees💰 Last funded 2018
Biotechnology Research🌐 epiodyne.com
Website LinkedIn
Epiodyne was founded to develop breakthrough small molecule medicines based upon novel insights into GPCR receptor pharmacology that were uncovered by leading researchers at UCSF, Stanford and Duke. Together with our founders and with the highly experienced medicinal chemistry team at R2M Pharma (https://www.linkedin.com/company/r2m-pharma/), we are using quantitative pharmacological and behavioral techniques to translate our insights into novel medicines for patients with opioid use disorder (OUD). We are backed by a syndicate of experienced biotech VCs and located in the Bay Area.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2016
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Epiodyne?
Epiodyne has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Epiodyne last raise funding?
The most recent investment in Epiodyne recorded on gritt.io was in 2018.
When was Epiodyne founded?
Epiodyne was founded in 2016.
What industry is Epiodyne in?
Epiodyne operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Epiodyne based?
Epiodyne is headquartered in San Francisco, United States.